NICE recommends Imcivree for obesity and hyperphagia in Bardet-Biedl syndrome from age 6 – Rhythm Pharmaceuticals
Setmelanotide can be used as an option to treat obesity and hyperphagia associated with genetically confirmed Bardet–Biedl syndrome (BBS) in people 6 years and over.
Setmelanotide can only be used if the company provides it according to the commercial arrangement. This recommendation is not intended to affect treatment with setmelanotide that was started in the NHS before this guidance was published.
Why the committee made these recommendations: This evaluation reviews the evidence for setmelanotide for treating obesity and hyperphagia (characterised by a feeling similar to starvation) associated with BBS. It is a review of NICE highly specialised technologies guidance 31 (HST31). HST31 recommended setmelanotide only for people with BBS who start treatment between age 6 and 17 years, with the option to continue treatment as adults until they need to stop. For this review, the committee considered evidence for people who start setmelanotide as adults and for the whole population, including children and adults. Usual treatment for obesity and hyperphagia for adults with BBS (who have not started setmelanotide before age 18 years) is best supportive care. This includes dietary restrictions and exercise to manage symptoms.
Results from clinical trials suggest that: i) setmelanotide may reduce weight and body mass index (BMI) in people 6 years and over with BBS; ii) hunger scores and quality of life are improved with setmelanotide in the short term, although hunger scores may not reliably reflect changes in hyperphagia. The updated trial evidence suggests that setmelanotide’s treatment effect on weight-related outcomes in both children and adults may be maintained in the longer term. But this is also uncertain. For the whole population (children and adults), the cost-effectiveness estimates are below the range normally considered an acceptable use of NHS resources.
So, setmelanotide can be used to treat obesity and hyperphagia in people with BBS aged 6 years and over.




